Research on patients with poorly controlled type 2 diabetes revealed those who used oral salsalate as an add-on to one to three diabetes drugs attained lower A1C rates at 48 weeks than those in the placebo group. Data also showed 41% of those in the salsalate group attained 0.5 percentage points or greater reductions in A1C at the study's conclusion, compared with 23% of those who took a placebo. The findings appear in the Annals of Internal Medicine.

Related Summaries